vaccine prophylaxis
PreclinicalVaccine
vaccine prophylaxis is one of 41 biologic programs targeting Mortality. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
108 competitors in Mortality
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaPhase 3
Mounjaro
Eli LillyPhase 3
Winrevair
Merck & Co.Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Peridex
MMedline Industries
Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Jardiance
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for vaccine prophylaxis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details